Neurol. praxi. 2010;11(6):396-399

The concept of mild cognitive impairment in Alzheimer’s disease and Parkinson’s disease

doc.MUDr.Irena Rektorová, Ph.D.
Centrum pro kognitivní poruchy, 1. neurologická klinika LF MU, FN u sv. Anny, Brno

Cognitive impairment exists in Parkinson’s disease (PD) as a transitional state between cognitively intact and demented PD patients. It seems

to be a risk factor for development of dementia in PD, but the precise criteria and “malignant” cognitive profile of mild cognitive impairment

in PD (MCI in PD) have not yet been established. The concept may turn to be different from that in Alzheimer’s disease (AD) since we search

for those already diagnosed PD patients who are at risk of developing dementia. In addition, clinical variables specific for PD also play role.

Importantly, MCI possesses a metabolic basis in PD. Various biomarkers including particularly neuropsychological testing, brain imaging,

and analysis of specific proteins in cerebrospinal fluid hold promise in identification of MCI in PD patients with unfavourable prognoses.

Well-designed longitudinal studies in MCI-PD cohorts are needed to assess the sensitivity and specificity of the PD-MCI designation as far

as dementia development is concerned.

Keywords: mild cognitive impairment, dementia, Alzheimer’s disease, Parkinson’s disease, executive functions, memory, biomarkers

Published: December 31, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rektorová I. The concept of mild cognitive impairment in Alzheimer’s disease and Parkinson’s disease. Neurol. praxi. 2010;11(6):396-399.
Download citation

References

  1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289: 18-22. Go to original source... Go to PubMed...
  2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-S?rensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92. Go to original source... Go to PubMed...
  3. Aarsland D, Br?nnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 928-930. Go to original source... Go to PubMed...
  4. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78: 254-259. Go to original source... Go to PubMed...
  5. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain patology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-210. Go to original source... Go to PubMed...
  6. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006; 248: 255-258. Go to original source... Go to PubMed...
  7. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277. Go to original source... Go to PubMed...
  8. Cools R. Dopaminergic modulation of cognitive function implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1-23. Go to original source... Go to PubMed...
  9. Dubois B. Is PD-MCI a useful concept? Mov Disord 2007; 22: 1215-1216. Go to original source... Go to PubMed...
  10. Dubois B, Feldman HH, Jacova C, Dekosky ST, BarbergerGateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol 2007; 6: 734-746. Go to original source... Go to PubMed...
  11. Emre M, Aarsland D, Brown, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementi associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707. Go to original source... Go to PubMed...
  12. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-560. Go to original source... Go to PubMed...
  13. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009; 24: 854-862. Go to original source... Go to PubMed...
  14. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70: 1470-1477. Go to original source... Go to PubMed...
  15. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148. Go to original source... Go to PubMed...
  16. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 1995; 45: 1691-1696. Go to original source... Go to PubMed...
  17. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149-154. Go to original source... Go to PubMed...
  18. Korczyn AD, Reichmann H. Dementia with Lewy bodies. J Neurol Sci 2006; 248: 3-8. Go to original source... Go to PubMed...
  19. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009; 24: 1103-1110. Go to original source... Go to PubMed...
  20. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106: 257-270. Go to original source... Go to PubMed...
  21. Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration- [18F] FDG-PET. Mov Disord 2009; 24: 1504-1511. Go to original source... Go to PubMed...
  22. Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-183. Go to original source... Go to PubMed...
  23. Mamikonyan E, Moberg PJ, Siderowf A, Duda JE, Have TT, Hurtig HI, Stern MB, Weintraub D. Mild cognitive impairment is common in Parkinson's disease patients with normal MiniMental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009; 15: 226-231. Go to original source... Go to PubMed...
  24. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245. Go to original source... Go to PubMed...
  25. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. BIOL PSYCHIATRY 2008; 64: 850-855. Go to original source... Go to PubMed...
  26. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194. Go to original source... Go to PubMed...
  27. Petersen RC, Smith GE, Waring SC, Vnik RJ, Tantalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308. Go to original source... Go to PubMed...
  28. Piccirilli M, D'Alessandro P, Finali G, Piccinin GL, Agostini L. Frontal lobe dysfunction in Parkinson's disease: prognostic value for dementia? Eur Neurol 1989; 29: 71-76. Go to original source... Go to PubMed...
  29. Rektorova I. Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease. Neurodegener Dis 2010; 7: 206-209. Go to original source... Go to PubMed...
  30. Rektorová I. Neurodegenerativní demence. Cesk Slov Neurol N 2009; 72/105: 97-109.
  31. Rektorova I, Rusina R, Hort J, Matej R. The Degenerative Dementias. In: Lisak RP, Truong DD, Carroll WM, Bhidayasiri R (eds.). International neurology: A clinical approach. Blackwsell Publishing 2009: 126-136. Go to original source...
  32. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-278. Go to original source... Go to PubMed...
  33. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, ChenPlotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyoid beta 1-42 predicts cognitive decline in Parkinson's disease. Neurology 2010; epub ahead of print. Go to original source... Go to PubMed...
  34. Tomer R, Aharon-Peretz J, Tsitrinbaum Z. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease. Neuropsychologia 2007; 45: 357-367. Go to original source... Go to PubMed...
  35. Tröster AI. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for, ,mild cognitive impairment" and biomarkers. Neuropsychol Rev 2008; 18: 103-119. Go to original source... Go to PubMed...
  36. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.